nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—GRIK4—renal system—uterine cancer	0.0134	0.102	CbGeAlD
Topiramate—CA6—exocrine gland—uterine cancer	0.0115	0.0868	CbGeAlD
Topiramate—GRIK3—mammalian vulva—uterine cancer	0.00917	0.0694	CbGeAlD
Topiramate—CYP2C19—Progesterone—uterine cancer	0.00813	0.388	CbGbCtD
Topiramate—GRIK3—female reproductive system—uterine cancer	0.00785	0.0594	CbGeAlD
Topiramate—GRIK3—vagina—uterine cancer	0.0071	0.0538	CbGeAlD
Topiramate—GRIK1—female gonad—uterine cancer	0.00679	0.0514	CbGeAlD
Topiramate—GRIK1—vagina—uterine cancer	0.00674	0.0511	CbGeAlD
Topiramate—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.00594	0.283	CbGbCtD
Topiramate—CA5A—female reproductive system—uterine cancer	0.00574	0.0435	CbGeAlD
Topiramate—CA7—renal system—uterine cancer	0.00477	0.0361	CbGeAlD
Topiramate—GRIK5—lymph node—uterine cancer	0.00459	0.0348	CbGeAlD
Topiramate—GRIK3—lymph node—uterine cancer	0.00459	0.0348	CbGeAlD
Topiramate—CA2—exocrine gland—uterine cancer	0.00394	0.0299	CbGeAlD
Topiramate—CYP3A4—Progesterone—uterine cancer	0.00393	0.188	CbGbCtD
Topiramate—CA9—female reproductive system—uterine cancer	0.00336	0.0254	CbGeAlD
Topiramate—CA12—renal system—uterine cancer	0.0031	0.0235	CbGeAlD
Topiramate—CA5B—mammalian vulva—uterine cancer	0.0026	0.0197	CbGeAlD
Topiramate—CA12—female reproductive system—uterine cancer	0.00248	0.0188	CbGeAlD
Topiramate—CA1—renal system—uterine cancer	0.00246	0.0186	CbGeAlD
Topiramate—CA5B—female reproductive system—uterine cancer	0.00223	0.0169	CbGeAlD
Topiramate—CA5B—vagina—uterine cancer	0.00201	0.0153	CbGeAlD
Topiramate—CA1—female reproductive system—uterine cancer	0.00197	0.0149	CbGeAlD
Topiramate—SCN5A—vagina—uterine cancer	0.00195	0.0148	CbGeAlD
Topiramate—CA4—renal system—uterine cancer	0.00192	0.0145	CbGeAlD
Topiramate—CYP3A4—Etoposide—uterine cancer	0.00176	0.0839	CbGbCtD
Topiramate—CA2—epithelium—uterine cancer	0.00172	0.013	CbGeAlD
Topiramate—CA2—smooth muscle tissue—uterine cancer	0.00165	0.0125	CbGeAlD
Topiramate—CA2—decidua—uterine cancer	0.00162	0.0123	CbGeAlD
Topiramate—CA2—renal system—uterine cancer	0.00159	0.0121	CbGeAlD
Topiramate—CA4—female reproductive system—uterine cancer	0.00154	0.0116	CbGeAlD
Topiramate—CA2—mammalian vulva—uterine cancer	0.00149	0.0113	CbGeAlD
Topiramate—CA4—female gonad—uterine cancer	0.0014	0.0106	CbGeAlD
Topiramate—CA5B—lymph node—uterine cancer	0.0013	0.00987	CbGeAlD
Topiramate—CA2—female reproductive system—uterine cancer	0.00127	0.00965	CbGeAlD
Topiramate—CYP2C19—vagina—uterine cancer	0.00126	0.00953	CbGeAlD
Topiramate—CYP3A4—Doxorubicin—uterine cancer	0.0012	0.0573	CbGbCtD
Topiramate—CA2—female gonad—uterine cancer	0.00116	0.00878	CbGeAlD
Topiramate—CA2—vagina—uterine cancer	0.00115	0.00873	CbGeAlD
Topiramate—CA1—lymph node—uterine cancer	0.00115	0.00871	CbGeAlD
Topiramate—CYP3A4—renal system—uterine cancer	0.00103	0.00778	CbGeAlD
Topiramate—CA4—lymph node—uterine cancer	0.000899	0.00681	CbGeAlD
Topiramate—CYP3A4—female reproductive system—uterine cancer	0.000822	0.00623	CbGeAlD
Topiramate—CA2—lymph node—uterine cancer	0.000746	0.00565	CbGeAlD
Topiramate—Abdominal distension—Doxorubicin—uterine cancer	0.000254	0.000318	CcSEcCtD
Topiramate—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000254	0.000318	CcSEcCtD
Topiramate—Asthma—Doxorubicin—uterine cancer	0.000253	0.000316	CcSEcCtD
Topiramate—Dysphagia—Doxorubicin—uterine cancer	0.000253	0.000316	CcSEcCtD
Topiramate—Pollakiuria—Epirubicin—uterine cancer	0.000252	0.000316	CcSEcCtD
Topiramate—Eosinophilia—Doxorubicin—uterine cancer	0.00025	0.000313	CcSEcCtD
Topiramate—Photosensitivity reaction—Epirubicin—uterine cancer	0.000249	0.000312	CcSEcCtD
Topiramate—Paraesthesia—Etoposide—uterine cancer	0.000249	0.000311	CcSEcCtD
Topiramate—Weight increased—Epirubicin—uterine cancer	0.000248	0.000311	CcSEcCtD
Topiramate—Pancreatitis—Doxorubicin—uterine cancer	0.000248	0.00031	CcSEcCtD
Topiramate—Weight decreased—Epirubicin—uterine cancer	0.000247	0.000309	CcSEcCtD
Topiramate—Dyspnoea—Etoposide—uterine cancer	0.000247	0.000309	CcSEcCtD
Topiramate—Hyperglycaemia—Epirubicin—uterine cancer	0.000246	0.000308	CcSEcCtD
Topiramate—Somnolence—Etoposide—uterine cancer	0.000246	0.000308	CcSEcCtD
Topiramate—Angina pectoris—Doxorubicin—uterine cancer	0.000246	0.000308	CcSEcCtD
Topiramate—Pneumonia—Epirubicin—uterine cancer	0.000245	0.000307	CcSEcCtD
Topiramate—Infestation NOS—Epirubicin—uterine cancer	0.000243	0.000305	CcSEcCtD
Topiramate—Infestation—Epirubicin—uterine cancer	0.000243	0.000305	CcSEcCtD
Topiramate—Vomiting—Dactinomycin—uterine cancer	0.000243	0.000305	CcSEcCtD
Topiramate—Bronchitis—Doxorubicin—uterine cancer	0.000243	0.000304	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000241	0.000302	CcSEcCtD
Topiramate—Rash—Dactinomycin—uterine cancer	0.000241	0.000302	CcSEcCtD
Topiramate—Decreased appetite—Etoposide—uterine cancer	0.000241	0.000301	CcSEcCtD
Topiramate—Pancytopenia—Doxorubicin—uterine cancer	0.00024	0.0003	CcSEcCtD
Topiramate—Renal failure—Epirubicin—uterine cancer	0.000239	0.0003	CcSEcCtD
Topiramate—Gastrointestinal disorder—Etoposide—uterine cancer	0.000239	0.000299	CcSEcCtD
Topiramate—Fatigue—Etoposide—uterine cancer	0.000239	0.000299	CcSEcCtD
Topiramate—Neuropathy peripheral—Epirubicin—uterine cancer	0.000239	0.000299	CcSEcCtD
Topiramate—Stomatitis—Epirubicin—uterine cancer	0.000237	0.000297	CcSEcCtD
Topiramate—Pain—Etoposide—uterine cancer	0.000237	0.000297	CcSEcCtD
Topiramate—Constipation—Etoposide—uterine cancer	0.000237	0.000297	CcSEcCtD
Topiramate—Urinary tract infection—Epirubicin—uterine cancer	0.000237	0.000296	CcSEcCtD
Topiramate—Conjunctivitis—Epirubicin—uterine cancer	0.000237	0.000296	CcSEcCtD
Topiramate—Dysuria—Doxorubicin—uterine cancer	0.000236	0.000296	CcSEcCtD
Topiramate—Neutropenia—Doxorubicin—uterine cancer	0.000236	0.000296	CcSEcCtD
Topiramate—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000235	0.000294	CcSEcCtD
Topiramate—Pollakiuria—Doxorubicin—uterine cancer	0.000233	0.000292	CcSEcCtD
Topiramate—Haematuria—Epirubicin—uterine cancer	0.000232	0.000291	CcSEcCtD
Topiramate—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000231	0.000289	CcSEcCtD
Topiramate—Weight increased—Doxorubicin—uterine cancer	0.00023	0.000288	CcSEcCtD
Topiramate—Epistaxis—Epirubicin—uterine cancer	0.00023	0.000287	CcSEcCtD
Topiramate—Weight decreased—Doxorubicin—uterine cancer	0.000228	0.000286	CcSEcCtD
Topiramate—Sinusitis—Epirubicin—uterine cancer	0.000228	0.000286	CcSEcCtD
Topiramate—Feeling abnormal—Etoposide—uterine cancer	0.000228	0.000286	CcSEcCtD
Topiramate—Hyperglycaemia—Doxorubicin—uterine cancer	0.000228	0.000285	CcSEcCtD
Topiramate—Nausea—Dactinomycin—uterine cancer	0.000227	0.000285	CcSEcCtD
Topiramate—Agranulocytosis—Epirubicin—uterine cancer	0.000227	0.000284	CcSEcCtD
Topiramate—Pneumonia—Doxorubicin—uterine cancer	0.000226	0.000284	CcSEcCtD
Topiramate—Gastrointestinal pain—Etoposide—uterine cancer	0.000226	0.000284	CcSEcCtD
Topiramate—Infestation NOS—Doxorubicin—uterine cancer	0.000225	0.000282	CcSEcCtD
Topiramate—Infestation—Doxorubicin—uterine cancer	0.000225	0.000282	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000223	0.00028	CcSEcCtD
Topiramate—Bradycardia—Epirubicin—uterine cancer	0.000222	0.000279	CcSEcCtD
Topiramate—Renal failure—Doxorubicin—uterine cancer	0.000221	0.000277	CcSEcCtD
Topiramate—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000221	0.000276	CcSEcCtD
Topiramate—Urticaria—Etoposide—uterine cancer	0.00022	0.000275	CcSEcCtD
Topiramate—Haemoglobin—Epirubicin—uterine cancer	0.00022	0.000275	CcSEcCtD
Topiramate—Stomatitis—Doxorubicin—uterine cancer	0.000219	0.000275	CcSEcCtD
Topiramate—Rhinitis—Epirubicin—uterine cancer	0.000219	0.000274	CcSEcCtD
Topiramate—Abdominal pain—Etoposide—uterine cancer	0.000219	0.000274	CcSEcCtD
Topiramate—Body temperature increased—Etoposide—uterine cancer	0.000219	0.000274	CcSEcCtD
Topiramate—Urinary tract infection—Doxorubicin—uterine cancer	0.000219	0.000274	CcSEcCtD
Topiramate—Conjunctivitis—Doxorubicin—uterine cancer	0.000219	0.000274	CcSEcCtD
Topiramate—Haemorrhage—Epirubicin—uterine cancer	0.000218	0.000274	CcSEcCtD
Topiramate—Hepatitis—Epirubicin—uterine cancer	0.000218	0.000274	CcSEcCtD
Topiramate—Hypoaesthesia—Epirubicin—uterine cancer	0.000217	0.000272	CcSEcCtD
Topiramate—Pharyngitis—Epirubicin—uterine cancer	0.000217	0.000272	CcSEcCtD
Topiramate—Urinary tract disorder—Epirubicin—uterine cancer	0.000216	0.00027	CcSEcCtD
Topiramate—Oedema peripheral—Epirubicin—uterine cancer	0.000215	0.00027	CcSEcCtD
Topiramate—Haematuria—Doxorubicin—uterine cancer	0.000215	0.000269	CcSEcCtD
Topiramate—Connective tissue disorder—Epirubicin—uterine cancer	0.000215	0.000269	CcSEcCtD
Topiramate—Urethral disorder—Epirubicin—uterine cancer	0.000214	0.000268	CcSEcCtD
Topiramate—Epistaxis—Doxorubicin—uterine cancer	0.000212	0.000266	CcSEcCtD
Topiramate—Sinusitis—Doxorubicin—uterine cancer	0.000211	0.000265	CcSEcCtD
Topiramate—Visual impairment—Epirubicin—uterine cancer	0.000211	0.000264	CcSEcCtD
Topiramate—Agranulocytosis—Doxorubicin—uterine cancer	0.00021	0.000263	CcSEcCtD
Topiramate—Erythema multiforme—Epirubicin—uterine cancer	0.000207	0.000259	CcSEcCtD
Topiramate—Bradycardia—Doxorubicin—uterine cancer	0.000206	0.000258	CcSEcCtD
Topiramate—Eye disorder—Epirubicin—uterine cancer	0.000204	0.000256	CcSEcCtD
Topiramate—Hypersensitivity—Etoposide—uterine cancer	0.000204	0.000255	CcSEcCtD
Topiramate—Tinnitus—Epirubicin—uterine cancer	0.000204	0.000255	CcSEcCtD
Topiramate—Haemoglobin—Doxorubicin—uterine cancer	0.000203	0.000254	CcSEcCtD
Topiramate—Flushing—Epirubicin—uterine cancer	0.000203	0.000254	CcSEcCtD
Topiramate—Cardiac disorder—Epirubicin—uterine cancer	0.000203	0.000254	CcSEcCtD
Topiramate—Rhinitis—Doxorubicin—uterine cancer	0.000203	0.000254	CcSEcCtD
Topiramate—Haemorrhage—Doxorubicin—uterine cancer	0.000202	0.000253	CcSEcCtD
Topiramate—Hepatitis—Doxorubicin—uterine cancer	0.000202	0.000253	CcSEcCtD
Topiramate—Hypoaesthesia—Doxorubicin—uterine cancer	0.000201	0.000252	CcSEcCtD
Topiramate—Pharyngitis—Doxorubicin—uterine cancer	0.000201	0.000251	CcSEcCtD
Topiramate—Urinary tract disorder—Doxorubicin—uterine cancer	0.0002	0.00025	CcSEcCtD
Topiramate—Oedema peripheral—Doxorubicin—uterine cancer	0.000199	0.000249	CcSEcCtD
Topiramate—Asthenia—Etoposide—uterine cancer	0.000199	0.000249	CcSEcCtD
Topiramate—Connective tissue disorder—Doxorubicin—uterine cancer	0.000199	0.000249	CcSEcCtD
Topiramate—Angiopathy—Epirubicin—uterine cancer	0.000198	0.000248	CcSEcCtD
Topiramate—Urethral disorder—Doxorubicin—uterine cancer	0.000198	0.000248	CcSEcCtD
Topiramate—Immune system disorder—Epirubicin—uterine cancer	0.000197	0.000247	CcSEcCtD
Topiramate—Mediastinal disorder—Epirubicin—uterine cancer	0.000197	0.000247	CcSEcCtD
Topiramate—Chills—Epirubicin—uterine cancer	0.000196	0.000245	CcSEcCtD
Topiramate—Pruritus—Etoposide—uterine cancer	0.000196	0.000245	CcSEcCtD
Topiramate—Visual impairment—Doxorubicin—uterine cancer	0.000195	0.000244	CcSEcCtD
Topiramate—Alopecia—Epirubicin—uterine cancer	0.000193	0.000242	CcSEcCtD
Topiramate—Mental disorder—Epirubicin—uterine cancer	0.000191	0.00024	CcSEcCtD
Topiramate—Erythema multiforme—Doxorubicin—uterine cancer	0.000191	0.000239	CcSEcCtD
Topiramate—Malnutrition—Epirubicin—uterine cancer	0.00019	0.000238	CcSEcCtD
Topiramate—Erythema—Epirubicin—uterine cancer	0.00019	0.000238	CcSEcCtD
Topiramate—Diarrhoea—Etoposide—uterine cancer	0.000189	0.000237	CcSEcCtD
Topiramate—Eye disorder—Doxorubicin—uterine cancer	0.000189	0.000237	CcSEcCtD
Topiramate—Tinnitus—Doxorubicin—uterine cancer	0.000188	0.000236	CcSEcCtD
Topiramate—Cardiac disorder—Doxorubicin—uterine cancer	0.000188	0.000235	CcSEcCtD
Topiramate—Flushing—Doxorubicin—uterine cancer	0.000188	0.000235	CcSEcCtD
Topiramate—Flatulence—Epirubicin—uterine cancer	0.000187	0.000235	CcSEcCtD
Topiramate—Tension—Epirubicin—uterine cancer	0.000187	0.000234	CcSEcCtD
Topiramate—Dysgeusia—Epirubicin—uterine cancer	0.000186	0.000233	CcSEcCtD
Topiramate—Nervousness—Epirubicin—uterine cancer	0.000185	0.000231	CcSEcCtD
Topiramate—Back pain—Epirubicin—uterine cancer	0.000184	0.00023	CcSEcCtD
Topiramate—Angiopathy—Doxorubicin—uterine cancer	0.000183	0.00023	CcSEcCtD
Topiramate—Dizziness—Etoposide—uterine cancer	0.000183	0.000229	CcSEcCtD
Topiramate—Muscle spasms—Epirubicin—uterine cancer	0.000183	0.000229	CcSEcCtD
Topiramate—Immune system disorder—Doxorubicin—uterine cancer	0.000183	0.000229	CcSEcCtD
Topiramate—Mediastinal disorder—Doxorubicin—uterine cancer	0.000182	0.000228	CcSEcCtD
Topiramate—Chills—Doxorubicin—uterine cancer	0.000181	0.000227	CcSEcCtD
Topiramate—Vision blurred—Epirubicin—uterine cancer	0.000179	0.000224	CcSEcCtD
Topiramate—Alopecia—Doxorubicin—uterine cancer	0.000179	0.000224	CcSEcCtD
Topiramate—Mental disorder—Doxorubicin—uterine cancer	0.000177	0.000222	CcSEcCtD
Topiramate—Ill-defined disorder—Epirubicin—uterine cancer	0.000176	0.000221	CcSEcCtD
Topiramate—Vomiting—Etoposide—uterine cancer	0.000176	0.00022	CcSEcCtD
Topiramate—Malnutrition—Doxorubicin—uterine cancer	0.000176	0.00022	CcSEcCtD
Topiramate—Erythema—Doxorubicin—uterine cancer	0.000176	0.00022	CcSEcCtD
Topiramate—Anaemia—Epirubicin—uterine cancer	0.000176	0.00022	CcSEcCtD
Topiramate—Agitation—Epirubicin—uterine cancer	0.000175	0.000219	CcSEcCtD
Topiramate—Rash—Etoposide—uterine cancer	0.000175	0.000219	CcSEcCtD
Topiramate—Dermatitis—Etoposide—uterine cancer	0.000174	0.000218	CcSEcCtD
Topiramate—Headache—Etoposide—uterine cancer	0.000173	0.000217	CcSEcCtD
Topiramate—Flatulence—Doxorubicin—uterine cancer	0.000173	0.000217	CcSEcCtD
Topiramate—Tension—Doxorubicin—uterine cancer	0.000173	0.000216	CcSEcCtD
Topiramate—Dysgeusia—Doxorubicin—uterine cancer	0.000172	0.000216	CcSEcCtD
Topiramate—Malaise—Epirubicin—uterine cancer	0.000172	0.000215	CcSEcCtD
Topiramate—Nervousness—Doxorubicin—uterine cancer	0.000171	0.000214	CcSEcCtD
Topiramate—Vertigo—Epirubicin—uterine cancer	0.000171	0.000214	CcSEcCtD
Topiramate—Syncope—Epirubicin—uterine cancer	0.000171	0.000214	CcSEcCtD
Topiramate—Leukopenia—Epirubicin—uterine cancer	0.00017	0.000213	CcSEcCtD
Topiramate—Back pain—Doxorubicin—uterine cancer	0.00017	0.000213	CcSEcCtD
Topiramate—Muscle spasms—Doxorubicin—uterine cancer	0.000169	0.000212	CcSEcCtD
Topiramate—Palpitations—Epirubicin—uterine cancer	0.000168	0.00021	CcSEcCtD
Topiramate—Loss of consciousness—Epirubicin—uterine cancer	0.000167	0.000209	CcSEcCtD
Topiramate—Cough—Epirubicin—uterine cancer	0.000166	0.000208	CcSEcCtD
Topiramate—Vision blurred—Doxorubicin—uterine cancer	0.000166	0.000208	CcSEcCtD
Topiramate—Convulsion—Epirubicin—uterine cancer	0.000165	0.000206	CcSEcCtD
Topiramate—Nausea—Etoposide—uterine cancer	0.000164	0.000206	CcSEcCtD
Topiramate—Hypertension—Epirubicin—uterine cancer	0.000164	0.000206	CcSEcCtD
Topiramate—Ill-defined disorder—Doxorubicin—uterine cancer	0.000163	0.000204	CcSEcCtD
Topiramate—Anaemia—Doxorubicin—uterine cancer	0.000163	0.000204	CcSEcCtD
Topiramate—Chest pain—Epirubicin—uterine cancer	0.000162	0.000203	CcSEcCtD
Topiramate—Myalgia—Epirubicin—uterine cancer	0.000162	0.000203	CcSEcCtD
Topiramate—Arthralgia—Epirubicin—uterine cancer	0.000162	0.000203	CcSEcCtD
Topiramate—Agitation—Doxorubicin—uterine cancer	0.000162	0.000203	CcSEcCtD
Topiramate—Anxiety—Epirubicin—uterine cancer	0.000161	0.000202	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000161	0.000201	CcSEcCtD
Topiramate—Discomfort—Epirubicin—uterine cancer	0.00016	0.0002	CcSEcCtD
Topiramate—Malaise—Doxorubicin—uterine cancer	0.000159	0.000199	CcSEcCtD
Topiramate—Dry mouth—Epirubicin—uterine cancer	0.000158	0.000198	CcSEcCtD
Topiramate—Vertigo—Doxorubicin—uterine cancer	0.000158	0.000198	CcSEcCtD
Topiramate—Syncope—Doxorubicin—uterine cancer	0.000158	0.000198	CcSEcCtD
Topiramate—Leukopenia—Doxorubicin—uterine cancer	0.000158	0.000197	CcSEcCtD
Topiramate—Confusional state—Epirubicin—uterine cancer	0.000157	0.000196	CcSEcCtD
Topiramate—Palpitations—Doxorubicin—uterine cancer	0.000156	0.000195	CcSEcCtD
Topiramate—Oedema—Epirubicin—uterine cancer	0.000155	0.000194	CcSEcCtD
Topiramate—Loss of consciousness—Doxorubicin—uterine cancer	0.000155	0.000194	CcSEcCtD
Topiramate—Infection—Epirubicin—uterine cancer	0.000154	0.000193	CcSEcCtD
Topiramate—Cough—Doxorubicin—uterine cancer	0.000154	0.000192	CcSEcCtD
Topiramate—Shock—Epirubicin—uterine cancer	0.000153	0.000191	CcSEcCtD
Topiramate—Convulsion—Doxorubicin—uterine cancer	0.000152	0.000191	CcSEcCtD
Topiramate—Nervous system disorder—Epirubicin—uterine cancer	0.000152	0.000191	CcSEcCtD
Topiramate—Thrombocytopenia—Epirubicin—uterine cancer	0.000152	0.00019	CcSEcCtD
Topiramate—Hypertension—Doxorubicin—uterine cancer	0.000152	0.00019	CcSEcCtD
Topiramate—Tachycardia—Epirubicin—uterine cancer	0.000151	0.00019	CcSEcCtD
Topiramate—Skin disorder—Epirubicin—uterine cancer	0.000151	0.000189	CcSEcCtD
Topiramate—Hyperhidrosis—Epirubicin—uterine cancer	0.00015	0.000188	CcSEcCtD
Topiramate—Chest pain—Doxorubicin—uterine cancer	0.00015	0.000188	CcSEcCtD
Topiramate—Arthralgia—Doxorubicin—uterine cancer	0.00015	0.000188	CcSEcCtD
Topiramate—Myalgia—Doxorubicin—uterine cancer	0.00015	0.000188	CcSEcCtD
Topiramate—Anxiety—Doxorubicin—uterine cancer	0.000149	0.000187	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000149	0.000186	CcSEcCtD
Topiramate—Discomfort—Doxorubicin—uterine cancer	0.000148	0.000185	CcSEcCtD
Topiramate—Anorexia—Epirubicin—uterine cancer	0.000148	0.000185	CcSEcCtD
Topiramate—Dry mouth—Doxorubicin—uterine cancer	0.000147	0.000183	CcSEcCtD
Topiramate—Hypotension—Epirubicin—uterine cancer	0.000145	0.000182	CcSEcCtD
Topiramate—Confusional state—Doxorubicin—uterine cancer	0.000145	0.000181	CcSEcCtD
Topiramate—Oedema—Doxorubicin—uterine cancer	0.000144	0.00018	CcSEcCtD
Topiramate—Infection—Doxorubicin—uterine cancer	0.000143	0.000179	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000141	0.000177	CcSEcCtD
Topiramate—Shock—Doxorubicin—uterine cancer	0.000141	0.000177	CcSEcCtD
Topiramate—Nervous system disorder—Doxorubicin—uterine cancer	0.000141	0.000176	CcSEcCtD
Topiramate—Thrombocytopenia—Doxorubicin—uterine cancer	0.000141	0.000176	CcSEcCtD
Topiramate—Insomnia—Epirubicin—uterine cancer	0.00014	0.000176	CcSEcCtD
Topiramate—Tachycardia—Doxorubicin—uterine cancer	0.00014	0.000176	CcSEcCtD
Topiramate—Skin disorder—Doxorubicin—uterine cancer	0.00014	0.000175	CcSEcCtD
Topiramate—Paraesthesia—Epirubicin—uterine cancer	0.000139	0.000175	CcSEcCtD
Topiramate—Hyperhidrosis—Doxorubicin—uterine cancer	0.000139	0.000174	CcSEcCtD
Topiramate—Dyspnoea—Epirubicin—uterine cancer	0.000138	0.000173	CcSEcCtD
Topiramate—Somnolence—Epirubicin—uterine cancer	0.000138	0.000173	CcSEcCtD
Topiramate—Anorexia—Doxorubicin—uterine cancer	0.000137	0.000171	CcSEcCtD
Topiramate—Dyspepsia—Epirubicin—uterine cancer	0.000137	0.000171	CcSEcCtD
Topiramate—Decreased appetite—Epirubicin—uterine cancer	0.000135	0.000169	CcSEcCtD
Topiramate—Hypotension—Doxorubicin—uterine cancer	0.000134	0.000168	CcSEcCtD
Topiramate—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000134	0.000168	CcSEcCtD
Topiramate—Fatigue—Epirubicin—uterine cancer	0.000134	0.000168	CcSEcCtD
Topiramate—Pain—Epirubicin—uterine cancer	0.000133	0.000166	CcSEcCtD
Topiramate—Constipation—Epirubicin—uterine cancer	0.000133	0.000166	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000131	0.000164	CcSEcCtD
Topiramate—Insomnia—Doxorubicin—uterine cancer	0.00013	0.000163	CcSEcCtD
Topiramate—Paraesthesia—Doxorubicin—uterine cancer	0.000129	0.000161	CcSEcCtD
Topiramate—Dyspnoea—Doxorubicin—uterine cancer	0.000128	0.00016	CcSEcCtD
Topiramate—Feeling abnormal—Epirubicin—uterine cancer	0.000128	0.00016	CcSEcCtD
Topiramate—Somnolence—Doxorubicin—uterine cancer	0.000128	0.00016	CcSEcCtD
Topiramate—Gastrointestinal pain—Epirubicin—uterine cancer	0.000127	0.000159	CcSEcCtD
Topiramate—Dyspepsia—Doxorubicin—uterine cancer	0.000126	0.000158	CcSEcCtD
Topiramate—Decreased appetite—Doxorubicin—uterine cancer	0.000125	0.000156	CcSEcCtD
Topiramate—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000124	0.000155	CcSEcCtD
Topiramate—Fatigue—Doxorubicin—uterine cancer	0.000124	0.000155	CcSEcCtD
Topiramate—Urticaria—Epirubicin—uterine cancer	0.000123	0.000154	CcSEcCtD
Topiramate—Constipation—Doxorubicin—uterine cancer	0.000123	0.000154	CcSEcCtD
Topiramate—Pain—Doxorubicin—uterine cancer	0.000123	0.000154	CcSEcCtD
Topiramate—Abdominal pain—Epirubicin—uterine cancer	0.000123	0.000154	CcSEcCtD
Topiramate—Body temperature increased—Epirubicin—uterine cancer	0.000123	0.000154	CcSEcCtD
Topiramate—Feeling abnormal—Doxorubicin—uterine cancer	0.000118	0.000148	CcSEcCtD
Topiramate—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000117	0.000147	CcSEcCtD
Topiramate—Hypersensitivity—Epirubicin—uterine cancer	0.000114	0.000143	CcSEcCtD
Topiramate—Urticaria—Doxorubicin—uterine cancer	0.000114	0.000143	CcSEcCtD
Topiramate—Abdominal pain—Doxorubicin—uterine cancer	0.000114	0.000142	CcSEcCtD
Topiramate—Body temperature increased—Doxorubicin—uterine cancer	0.000114	0.000142	CcSEcCtD
Topiramate—Asthenia—Epirubicin—uterine cancer	0.000111	0.000139	CcSEcCtD
Topiramate—SCN1A—Axon guidance—MET—uterine cancer	0.000111	0.00229	CbGpPWpGaD
Topiramate—CA12—Metabolism—POLD1—uterine cancer	0.00011	0.00228	CbGpPWpGaD
Topiramate—Pruritus—Epirubicin—uterine cancer	0.00011	0.000138	CcSEcCtD
Topiramate—CA2—Metabolism—STAR—uterine cancer	0.000107	0.00222	CbGpPWpGaD
Topiramate—CA2—Metabolism—AKR1B1—uterine cancer	0.000107	0.00222	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	0.000107	0.00221	CbGpPWpGaD
Topiramate—CA6—Metabolism—RRM2—uterine cancer	0.000106	0.00219	CbGpPWpGaD
Topiramate—CA5A—Metabolism—RRM2—uterine cancer	0.000106	0.00219	CbGpPWpGaD
Topiramate—Diarrhoea—Epirubicin—uterine cancer	0.000106	0.000133	CcSEcCtD
Topiramate—Hypersensitivity—Doxorubicin—uterine cancer	0.000106	0.000133	CcSEcCtD
Topiramate—GABRA1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000105	0.00217	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—CTNNB1—uterine cancer	0.000105	0.00216	CbGpPWpGaD
Topiramate—CA5A—Metabolism—DCN—uterine cancer	0.000103	0.00213	CbGpPWpGaD
Topiramate—CA6—Metabolism—DCN—uterine cancer	0.000103	0.00213	CbGpPWpGaD
Topiramate—CA12—Metabolism—AKR1C1—uterine cancer	0.000103	0.00213	CbGpPWpGaD
Topiramate—Asthenia—Doxorubicin—uterine cancer	0.000103	0.000129	CcSEcCtD
Topiramate—CA1—Metabolism—AKR1B1—uterine cancer	0.000103	0.00213	CbGpPWpGaD
Topiramate—CA1—Metabolism—STAR—uterine cancer	0.000103	0.00213	CbGpPWpGaD
Topiramate—Dizziness—Epirubicin—uterine cancer	0.000103	0.000129	CcSEcCtD
Topiramate—Pruritus—Doxorubicin—uterine cancer	0.000102	0.000127	CcSEcCtD
Topiramate—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.0001	0.00207	CbGpPWpGaD
Topiramate—CA5B—Metabolism—RRM2—uterine cancer	9.92e-05	0.00205	CbGpPWpGaD
Topiramate—CA7—Metabolism—RRM2—uterine cancer	9.92e-05	0.00205	CbGpPWpGaD
Topiramate—Vomiting—Epirubicin—uterine cancer	9.87e-05	0.000124	CcSEcCtD
Topiramate—Diarrhoea—Doxorubicin—uterine cancer	9.83e-05	0.000123	CcSEcCtD
Topiramate—Rash—Epirubicin—uterine cancer	9.79e-05	0.000123	CcSEcCtD
Topiramate—Dermatitis—Epirubicin—uterine cancer	9.78e-05	0.000122	CcSEcCtD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	9.73e-05	0.00201	CbGpPWpGaD
Topiramate—Headache—Epirubicin—uterine cancer	9.72e-05	0.000122	CcSEcCtD
Topiramate—CA6—Metabolism—CYP11A1—uterine cancer	9.72e-05	0.00201	CbGpPWpGaD
Topiramate—CA5A—Metabolism—CYP11A1—uterine cancer	9.72e-05	0.00201	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—CXCL8—uterine cancer	9.69e-05	0.002	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—SMAD3—uterine cancer	9.65e-05	0.00199	CbGpPWpGaD
Topiramate—CA5B—Metabolism—DCN—uterine cancer	9.63e-05	0.00199	CbGpPWpGaD
Topiramate—CA7—Metabolism—DCN—uterine cancer	9.63e-05	0.00199	CbGpPWpGaD
Topiramate—GRIA1—BDNF signaling pathway—HRAS—uterine cancer	9.51e-05	0.00196	CbGpPWpGaD
Topiramate—Dizziness—Doxorubicin—uterine cancer	9.5e-05	0.000119	CcSEcCtD
Topiramate—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	9.46e-05	0.00195	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	9.42e-05	0.00194	CbGpPWpGaD
Topiramate—GRIA3—Neuronal System—HRAS—uterine cancer	9.35e-05	0.00193	CbGpPWpGaD
Topiramate—Nausea—Epirubicin—uterine cancer	9.22e-05	0.000115	CcSEcCtD
Topiramate—CA12—Metabolism—RRM2—uterine cancer	9.19e-05	0.0019	CbGpPWpGaD
Topiramate—CA6—Metabolism—AKR1C3—uterine cancer	9.18e-05	0.00189	CbGpPWpGaD
Topiramate—CA5A—Metabolism—AKR1C3—uterine cancer	9.18e-05	0.00189	CbGpPWpGaD
Topiramate—Vomiting—Doxorubicin—uterine cancer	9.13e-05	0.000114	CcSEcCtD
Topiramate—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	9.11e-05	0.00188	CbGpPWpGaD
Topiramate—CA5B—Metabolism—CYP11A1—uterine cancer	9.07e-05	0.00187	CbGpPWpGaD
Topiramate—CA7—Metabolism—CYP11A1—uterine cancer	9.07e-05	0.00187	CbGpPWpGaD
Topiramate—Rash—Doxorubicin—uterine cancer	9.06e-05	0.000113	CcSEcCtD
Topiramate—CA9—Metabolism—STAR—uterine cancer	9.05e-05	0.00187	CbGpPWpGaD
Topiramate—CA9—Metabolism—AKR1B1—uterine cancer	9.05e-05	0.00187	CbGpPWpGaD
Topiramate—Dermatitis—Doxorubicin—uterine cancer	9.05e-05	0.000113	CcSEcCtD
Topiramate—Headache—Doxorubicin—uterine cancer	9e-05	0.000113	CcSEcCtD
Topiramate—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	8.99e-05	0.00186	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	8.94e-05	0.00184	CbGpPWpGaD
Topiramate—CA12—Metabolism—DCN—uterine cancer	8.92e-05	0.00184	CbGpPWpGaD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	8.9e-05	0.00184	CbGpPWpGaD
Topiramate—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	8.87e-05	0.00183	CbGpPWpGaD
Topiramate—CA4—Metabolism—POLD1—uterine cancer	8.79e-05	0.00181	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	8.79e-05	0.00181	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	8.75e-05	0.00181	CbGpPWpGaD
Topiramate—CA5B—Metabolism—AKR1C3—uterine cancer	8.57e-05	0.00177	CbGpPWpGaD
Topiramate—CA7—Metabolism—AKR1C3—uterine cancer	8.57e-05	0.00177	CbGpPWpGaD
Topiramate—Nausea—Doxorubicin—uterine cancer	8.53e-05	0.000107	CcSEcCtD
Topiramate—CA9—Cellular responses to stress—CDKN2A—uterine cancer	8.48e-05	0.00175	CbGpPWpGaD
Topiramate—CA2—Metabolism—POLD1—uterine cancer	8.43e-05	0.00174	CbGpPWpGaD
Topiramate—CA12—Metabolism—CYP11A1—uterine cancer	8.41e-05	0.00174	CbGpPWpGaD
Topiramate—GRIA1—BDNF signaling pathway—AKT1—uterine cancer	8.4e-05	0.00173	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—EP300—uterine cancer	8.31e-05	0.00171	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	8.26e-05	0.0017	CbGpPWpGaD
Topiramate—CA4—Metabolism—AKR1C1—uterine cancer	8.22e-05	0.0017	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—ERBB2—uterine cancer	8.1e-05	0.00167	CbGpPWpGaD
Topiramate—CA1—Metabolism—POLD1—uterine cancer	8.08e-05	0.00167	CbGpPWpGaD
Topiramate—CA12—Metabolism—AKR1C3—uterine cancer	7.94e-05	0.00164	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MET—uterine cancer	7.9e-05	0.00163	CbGpPWpGaD
Topiramate—CA2—Metabolism—AKR1C1—uterine cancer	7.88e-05	0.00163	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	7.87e-05	0.00162	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—VEGFA—uterine cancer	7.87e-05	0.00162	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—MET—uterine cancer	7.79e-05	0.00161	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—CXCL8—uterine cancer	7.69e-05	0.00159	CbGpPWpGaD
Topiramate—CA1—Metabolism—AKR1C1—uterine cancer	7.56e-05	0.00156	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—CDKN1B—uterine cancer	7.51e-05	0.00155	CbGpPWpGaD
Topiramate—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.39e-05	0.00152	CbGpPWpGaD
Topiramate—CA4—Metabolism—RRM2—uterine cancer	7.33e-05	0.00151	CbGpPWpGaD
Topiramate—GRIA1—Transmission across Chemical Synapses—HRAS—uterine cancer	7.31e-05	0.00151	CbGpPWpGaD
Topiramate—CA6—Metabolism—STK11—uterine cancer	7.15e-05	0.00148	CbGpPWpGaD
Topiramate—CA5A—Metabolism—STK11—uterine cancer	7.15e-05	0.00148	CbGpPWpGaD
Topiramate—CA6—Metabolism—CYP19A1—uterine cancer	7.15e-05	0.00148	CbGpPWpGaD
Topiramate—CA5A—Metabolism—CYP19A1—uterine cancer	7.15e-05	0.00148	CbGpPWpGaD
Topiramate—CA4—Metabolism—DCN—uterine cancer	7.12e-05	0.00147	CbGpPWpGaD
Topiramate—CA9—Metabolism—POLD1—uterine cancer	7.1e-05	0.00147	CbGpPWpGaD
Topiramate—CA2—Metabolism—RRM2—uterine cancer	7.03e-05	0.00145	CbGpPWpGaD
Topiramate—CA2—Metabolism—DCN—uterine cancer	6.82e-05	0.00141	CbGpPWpGaD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	6.8e-05	0.0014	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—SMAD3—uterine cancer	6.78e-05	0.0014	CbGpPWpGaD
Topiramate—CA1—Metabolism—RRM2—uterine cancer	6.74e-05	0.00139	CbGpPWpGaD
Topiramate—CA4—Metabolism—CYP11A1—uterine cancer	6.7e-05	0.00138	CbGpPWpGaD
Topiramate—GRIK2—Transmission across Chemical Synapses—HRAS—uterine cancer	6.69e-05	0.00138	CbGpPWpGaD
Topiramate—CA5B—Metabolism—STK11—uterine cancer	6.68e-05	0.00138	CbGpPWpGaD
Topiramate—CA7—Metabolism—STK11—uterine cancer	6.68e-05	0.00138	CbGpPWpGaD
Topiramate—CA7—Metabolism—CYP19A1—uterine cancer	6.68e-05	0.00138	CbGpPWpGaD
Topiramate—CA5B—Metabolism—CYP19A1—uterine cancer	6.68e-05	0.00138	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—HRAS—uterine cancer	6.65e-05	0.00137	CbGpPWpGaD
Topiramate—CA9—Metabolism—AKR1C1—uterine cancer	6.65e-05	0.00137	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—EP300—uterine cancer	6.6e-05	0.00136	CbGpPWpGaD
Topiramate—CA1—Metabolism—DCN—uterine cancer	6.54e-05	0.00135	CbGpPWpGaD
Topiramate—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	6.52e-05	0.00135	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	6.45e-05	0.00133	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	6.43e-05	0.00133	CbGpPWpGaD
Topiramate—CA2—Metabolism—CYP11A1—uterine cancer	6.43e-05	0.00133	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	6.38e-05	0.00132	CbGpPWpGaD
Topiramate—CA4—Metabolism—AKR1C3—uterine cancer	6.33e-05	0.00131	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—VEGFA—uterine cancer	6.25e-05	0.00129	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—VEGFA—uterine cancer	6.24e-05	0.00129	CbGpPWpGaD
Topiramate—CA12—Metabolism—CYP19A1—uterine cancer	6.19e-05	0.00128	CbGpPWpGaD
Topiramate—CA12—Metabolism—STK11—uterine cancer	6.19e-05	0.00128	CbGpPWpGaD
Topiramate—CA1—Metabolism—CYP11A1—uterine cancer	6.16e-05	0.00127	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—NRAS—uterine cancer	6.16e-05	0.00127	CbGpPWpGaD
Topiramate—CA2—Metabolism—AKR1C3—uterine cancer	6.07e-05	0.00125	CbGpPWpGaD
Topiramate—CA9—Metabolism—RRM2—uterine cancer	5.92e-05	0.00122	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	5.89e-05	0.00122	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—AKT1—uterine cancer	5.87e-05	0.00121	CbGpPWpGaD
Topiramate—CA1—Metabolism—AKR1C3—uterine cancer	5.82e-05	0.0012	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—ERBB2—uterine cancer	5.78e-05	0.00119	CbGpPWpGaD
Topiramate—CA9—Metabolism—DCN—uterine cancer	5.75e-05	0.00119	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—ERBB2—uterine cancer	5.69e-05	0.00117	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.69e-05	0.00117	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.69e-05	0.00117	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	5.66e-05	0.00117	CbGpPWpGaD
Topiramate—GRIA1—Neuronal System—HRAS—uterine cancer	5.6e-05	0.00116	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MET—uterine cancer	5.56e-05	0.00115	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—EP300—uterine cancer	5.47e-05	0.00113	CbGpPWpGaD
Topiramate—CA9—Metabolism—CYP11A1—uterine cancer	5.42e-05	0.00112	CbGpPWpGaD
Topiramate—CA5A—Metabolism—MTHFR—uterine cancer	5.37e-05	0.00111	CbGpPWpGaD
Topiramate—CA6—Metabolism—MTHFR—uterine cancer	5.37e-05	0.00111	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	5.33e-05	0.0011	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—KRAS—uterine cancer	5.3e-05	0.00109	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	5.26e-05	0.00109	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	5.18e-05	0.00107	CbGpPWpGaD
Topiramate—GRIK2—Neuronal System—HRAS—uterine cancer	5.12e-05	0.00106	CbGpPWpGaD
Topiramate—CA9—Metabolism—AKR1C3—uterine cancer	5.12e-05	0.00106	CbGpPWpGaD
Topiramate—GRIA2—Transmission across Chemical Synapses—HRAS—uterine cancer	5.11e-05	0.00106	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	5.11e-05	0.00105	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—CTNNB1—uterine cancer	5.05e-05	0.00104	CbGpPWpGaD
Topiramate—CA5B—Metabolism—MTHFR—uterine cancer	5.02e-05	0.00104	CbGpPWpGaD
Topiramate—CA7—Metabolism—MTHFR—uterine cancer	5.02e-05	0.00104	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	4.97e-05	0.00103	CbGpPWpGaD
Topiramate—CA4—Metabolism—STK11—uterine cancer	4.93e-05	0.00102	CbGpPWpGaD
Topiramate—CA4—Metabolism—CYP19A1—uterine cancer	4.93e-05	0.00102	CbGpPWpGaD
Topiramate—CA2—Metabolism—STK11—uterine cancer	4.73e-05	0.000976	CbGpPWpGaD
Topiramate—CA2—Metabolism—CYP19A1—uterine cancer	4.73e-05	0.000976	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—TP53—uterine cancer	4.72e-05	0.000974	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—EP300—uterine cancer	4.7e-05	0.00097	CbGpPWpGaD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	4.67e-05	0.000964	CbGpPWpGaD
Topiramate—CA12—Metabolism—MTHFR—uterine cancer	4.65e-05	0.000959	CbGpPWpGaD
Topiramate—CA1—Metabolism—STK11—uterine cancer	4.53e-05	0.000936	CbGpPWpGaD
Topiramate—CA1—Metabolism—CYP19A1—uterine cancer	4.53e-05	0.000936	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—HRAS—uterine cancer	4.51e-05	0.00093	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—VEGFA—uterine cancer	4.45e-05	0.000918	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—NRAS—uterine cancer	4.4e-05	0.000907	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—VEGFA—uterine cancer	4.38e-05	0.000905	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—NRAS—uterine cancer	4.33e-05	0.000894	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.18e-05	0.000862	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	4.08e-05	0.000843	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—ERBB2—uterine cancer	4.06e-05	0.000838	CbGpPWpGaD
Topiramate—CA9—Metabolism—STK11—uterine cancer	3.99e-05	0.000823	CbGpPWpGaD
Topiramate—CA9—Metabolism—CYP19A1—uterine cancer	3.99e-05	0.000823	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	3.92e-05	0.00081	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—HRAS—uterine cancer	3.92e-05	0.000809	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	3.87e-05	0.000799	CbGpPWpGaD
Topiramate—GABRB2—Transmission across Chemical Synapses—HRAS—uterine cancer	3.84e-05	0.000793	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—KRAS—uterine cancer	3.78e-05	0.000781	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—KRAS—uterine cancer	3.73e-05	0.000769	CbGpPWpGaD
Topiramate—CA4—Metabolism—MTHFR—uterine cancer	3.71e-05	0.000765	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—CTNNB1—uterine cancer	3.55e-05	0.000733	CbGpPWpGaD
Topiramate—CA2—Metabolism—MTHFR—uterine cancer	3.55e-05	0.000733	CbGpPWpGaD
Topiramate—GABRG2—Transmission across Chemical Synapses—HRAS—uterine cancer	3.51e-05	0.000725	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—NDUFB11—uterine cancer	3.51e-05	0.000724	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—SRD5A2—uterine cancer	3.51e-05	0.000724	CbGpPWpGaD
Topiramate—CA1—Metabolism—MTHFR—uterine cancer	3.41e-05	0.000703	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.41e-05	0.000703	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—EP300—uterine cancer	3.3e-05	0.000682	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.22e-05	0.000664	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—HRAS—uterine cancer	3.22e-05	0.000664	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—HRAS—uterine cancer	3.17e-05	0.000654	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—VEGFA—uterine cancer	3.13e-05	0.000646	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—NRAS—uterine cancer	3.09e-05	0.000638	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—HRAS—uterine cancer	3.07e-05	0.000634	CbGpPWpGaD
Topiramate—CA9—Metabolism—MTHFR—uterine cancer	3e-05	0.000618	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PTEN—uterine cancer	2.99e-05	0.000617	CbGpPWpGaD
Topiramate—CA6—Metabolism—PTEN—uterine cancer	2.99e-05	0.000617	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—HRAS—uterine cancer	2.94e-05	0.000607	CbGpPWpGaD
Topiramate—CA6—Metabolism—EP300—uterine cancer	2.85e-05	0.000588	CbGpPWpGaD
Topiramate—CA5A—Metabolism—EP300—uterine cancer	2.85e-05	0.000588	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—AKT1—uterine cancer	2.84e-05	0.000586	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PTEN—uterine cancer	2.79e-05	0.000576	CbGpPWpGaD
Topiramate—CA7—Metabolism—PTEN—uterine cancer	2.79e-05	0.000576	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—HRAS—uterine cancer	2.69e-05	0.000555	CbGpPWpGaD
Topiramate—CA5B—Metabolism—EP300—uterine cancer	2.66e-05	0.000549	CbGpPWpGaD
Topiramate—CA7—Metabolism—EP300—uterine cancer	2.66e-05	0.000549	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—KRAS—uterine cancer	2.66e-05	0.000549	CbGpPWpGaD
Topiramate—CA12—Metabolism—PTEN—uterine cancer	2.59e-05	0.000534	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—STAR—uterine cancer	2.53e-05	0.000523	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—AKR1B1—uterine cancer	2.53e-05	0.000523	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.51e-05	0.000517	CbGpPWpGaD
Topiramate—CA12—Metabolism—EP300—uterine cancer	2.47e-05	0.000509	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—HRAS—uterine cancer	2.35e-05	0.000486	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—HRAS—uterine cancer	2.26e-05	0.000467	CbGpPWpGaD
Topiramate—CA6—Metabolism—PIK3CA—uterine cancer	2.11e-05	0.000435	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PIK3CA—uterine cancer	2.11e-05	0.000435	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.11e-05	0.000435	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.11e-05	0.000435	CbGpPWpGaD
Topiramate—CA4—Metabolism—PTEN—uterine cancer	2.06e-05	0.000426	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—AKT1—uterine cancer	2e-05	0.000412	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—POLD1—uterine cancer	1.99e-05	0.00041	CbGpPWpGaD
Topiramate—CA2—Metabolism—PTEN—uterine cancer	1.98e-05	0.000408	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PIK3CA—uterine cancer	1.97e-05	0.000406	CbGpPWpGaD
Topiramate—CA7—Metabolism—PIK3CA—uterine cancer	1.97e-05	0.000406	CbGpPWpGaD
Topiramate—CA4—Metabolism—EP300—uterine cancer	1.97e-05	0.000406	CbGpPWpGaD
Topiramate—CA1—Metabolism—PTEN—uterine cancer	1.9e-05	0.000391	CbGpPWpGaD
Topiramate—CA2—Metabolism—EP300—uterine cancer	1.89e-05	0.000389	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.86e-05	0.000384	CbGpPWpGaD
Topiramate—CA12—Metabolism—PIK3CA—uterine cancer	1.82e-05	0.000376	CbGpPWpGaD
Topiramate—CA1—Metabolism—EP300—uterine cancer	1.81e-05	0.000373	CbGpPWpGaD
Topiramate—CA5A—Metabolism—AKT1—uterine cancer	1.72e-05	0.000356	CbGpPWpGaD
Topiramate—CA6—Metabolism—AKT1—uterine cancer	1.72e-05	0.000356	CbGpPWpGaD
Topiramate—CA9—Metabolism—PTEN—uterine cancer	1.67e-05	0.000344	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—RRM2—uterine cancer	1.66e-05	0.000342	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—DCN—uterine cancer	1.61e-05	0.000332	CbGpPWpGaD
Topiramate—CA7—Metabolism—AKT1—uterine cancer	1.61e-05	0.000332	CbGpPWpGaD
Topiramate—CA5B—Metabolism—AKT1—uterine cancer	1.61e-05	0.000332	CbGpPWpGaD
Topiramate—CA9—Metabolism—EP300—uterine cancer	1.59e-05	0.000328	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—STAR—uterine cancer	1.52e-05	0.000315	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.52e-05	0.000315	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.52e-05	0.000313	CbGpPWpGaD
Topiramate—CA12—Metabolism—AKT1—uterine cancer	1.49e-05	0.000308	CbGpPWpGaD
Topiramate—CA4—Metabolism—PIK3CA—uterine cancer	1.45e-05	0.0003	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.43e-05	0.000296	CbGpPWpGaD
Topiramate—CA2—Metabolism—PIK3CA—uterine cancer	1.39e-05	0.000288	CbGpPWpGaD
Topiramate—CA1—Metabolism—PIK3CA—uterine cancer	1.34e-05	0.000276	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—POLD1—uterine cancer	1.2e-05	0.000247	CbGpPWpGaD
Topiramate—CA4—Metabolism—AKT1—uterine cancer	1.19e-05	0.000245	CbGpPWpGaD
Topiramate—CA9—Metabolism—PIK3CA—uterine cancer	1.18e-05	0.000243	CbGpPWpGaD
Topiramate—CA2—Metabolism—AKT1—uterine cancer	1.14e-05	0.000235	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.12e-05	0.000231	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—STK11—uterine cancer	1.12e-05	0.00023	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CYP19A1—uterine cancer	1.12e-05	0.00023	CbGpPWpGaD
Topiramate—CA1—Metabolism—AKT1—uterine cancer	1.09e-05	0.000225	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.05e-05	0.000216	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.99e-06	0.000206	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—RRM2—uterine cancer	9.97e-06	0.000206	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—DCN—uterine cancer	9.68e-06	0.0002	CbGpPWpGaD
Topiramate—CA9—Metabolism—AKT1—uterine cancer	9.6e-06	0.000198	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—CYP11A1—uterine cancer	9.12e-06	0.000188	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—AKR1C3—uterine cancer	8.61e-06	0.000178	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—MTHFR—uterine cancer	8.38e-06	0.000173	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.39e-06	0.000152	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—STK11—uterine cancer	6.71e-06	0.000138	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—CYP19A1—uterine cancer	6.71e-06	0.000138	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—MTHFR—uterine cancer	5.04e-06	0.000104	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PTEN—uterine cancer	4.66e-06	9.63e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—EP300—uterine cancer	4.45e-06	9.18e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PIK3CA—uterine cancer	3.29e-06	6.79e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PTEN—uterine cancer	2.8e-06	5.79e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—AKT1—uterine cancer	2.69e-06	5.55e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—EP300—uterine cancer	2.67e-06	5.52e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.98e-06	4.08e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—AKT1—uterine cancer	1.62e-06	3.34e-05	CbGpPWpGaD
